Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.

The British journal of dermatology - 1 May 2017

van den Reek J M P A, Coenen M J H, van de L'Isle Arias M, Zweegers J, Rodijk-Olthuis D, Schalkwijk J, Vermeulen S H, Joosten I, van de Kerkhof P C M, Seyger M M B, Zeeuwen P L J M, de Jong E M G J

Abstract excerpt

BACKGROUND: The effectiveness of biologics for psoriasis shows heterogeneity among patients. With pharmacogenetic markers, it might be possible to predict treatment response. OBJECTIVES: We aimed to test the association between genetic markers and the response to biologics in psoriasis (etanercept, adalimumab, ustekinumab) in a prospective cohort. METHODS: We investigated the copy number variation in the LCE3B...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Biological Products

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dermatologic Agents

Share to Etanercept

Share to Interleukin-12 Subunit p40

Share to Psoriasis

Share to Treatment Outcome

Share to Tumor Necrosis Factor alpha-Induced Protein 3

Source

Identifiers

PMID: 27564082
DOI: 10.1111/bjd.15005

Genes

TNFAIP3
ERAP1
IFIH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.PMID 27564082Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.Semantic proximity Read ↗

Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.Semantic proximity Read ↗

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.Semantic proximity Read ↗

Genetics of Psoriasis and Pharmacogenetics of Biological DrugsSemantic proximity Read ↗

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated ReviewSemantic proximity Read ↗

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.Semantic proximity Read ↗

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.Semantic proximity Read ↗

The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe PsoriasisSemantic proximity Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.